Dramatic response to fourth-line ramucirumab after atezolizumab plus bevacizumab failure in advanced hepatocellular carcinoma: A case report

Figure 2 Progression chart during ramucirumab administration. Ramucirumab (RAM) was initiated as a fourth-line treatment 20 months after the initiation of systemic therapy. Magnetic resonance imaging performed 6 months after RAM administration revealed marked tumor shrinkage. The sum of the longest diameters of the two target hepatic lesions decreased from 95 mm to 40 mm, while the longest diameter of the extrahepatic lesion decreased from 108 mm to 28 mm, corresponding to a partial response according to the Response Evaluation Criteria in Solid Tumors version 1.1. The tumors are indicated by white arrowheads. The maximum tumor diameters are indicated by white lines, with the corresponding measurements (mm) shown. PR: Partial response; q2w: Every 2 weeks; q3w: Every 3 weeks; RAM: Ramucirumab; SD: Stable disease; DCP: Des-gamma carboxyprothrombin; AFP: Alpha-fetoprotein; ALBI: Albumin-bilirubin; SOR: Sorafenib.